Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Core Insights - Liquidia Corporation will present a poster and host a medical theater at the CHEST 2024 annual meeting from October 6-9, 2024, in Boston, focusing on their ongoing ASCENT trial for YUTREPIA™ [1][2] Group 1: Presentation Details - The poster presentation titled "Baseline Characteristics of Patients Enrolled in the ASCENT Study" will occur on October 9, 2024, from 10:20 a.m. to 11:05 a.m. ET, highlighting the safety and tolerability of YUTREPIA in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The medical theater will take place on October 7, 2024, from 12:15 p.m. to 1:00 p.m. ET, discussing current epidemiologic data on PH-ILD and the clinical data gap regarding dry-powder treprostinil use [3] Group 2: Product Information - YUTREPIA is an investigational inhaled dry-powder formulation of treprostinil, designed for enhanced lung deposition, and received tentative FDA approval for pulmonary arterial hypertension (PAH) in November 2021 [4] - Liquidia has filed an amendment to its New Drug Application for YUTREPIA to include PH-ILD in the label, and the product is currently being studied in the ASCENT trial to evaluate its dosing and tolerability profile [4] Group 3: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a particular emphasis on pulmonary hypertension and applications of its proprietary PRINT® technology [5] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [5]